Welcome to our dedicated page for Verona Pharma SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings for Verona Pharma plc, which previously traded on the Nasdaq Global Market under the ticker VRNA. Verona Pharma was a biopharmaceutical company focused on chronic respiratory diseases, with its lead product Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients. Its SEC filings document both its development and commercialization activities and the corporate steps that resulted in its acquisition by Merck.
Among the most important filings for VRNA are its Current Reports on Form 8-K. These include detailed descriptions of the July 2025 transaction agreement under which Merck Sharp & Dohme LLC, through a wholly owned subsidiary, agreed to acquire Verona Pharma by means of a court-sanctioned English law scheme of arrangement. Subsequent 8-K filings report shareholder voting results approving the transaction, amendments to Verona’s change-in-control severance plan, and the completion of the acquisition on October 7, 2025, when Merck’s acquisition vehicle obtained all issued and outstanding Verona shares and Verona became an indirect wholly owned subsidiary of Merck.
For trading status and listing history, users can review the Form 25 (Form 25-NSE) filed in connection with the delisting of Verona Pharma’s American Depositary Shares from the Nasdaq Stock Market LLC. The Form 25 identifies Verona Pharma as the issuer and serves as the official notification of removal from listing and/or registration under Section 12(b) of the Exchange Act. Related 8-K disclosures explain Verona’s request for suspension of trading in its ADSs, the plan to file a Form 15 to terminate registration of its shares and ADSs, and the resulting suspension of its reporting obligations under Sections 13(a) and 15(d).
Earlier 8-K filings also describe governance and compensation matters linked to the transaction, such as the voting agreement with certain directors and executive officers to support the scheme of arrangement and changes to the company’s severance plan in the context of a change in control. Together, these filings offer a regulatory record of how Verona Pharma moved from being an independent Nasdaq-listed issuer to a wholly owned subsidiary within Merck’s corporate structure.
On Stock Titan, these VRNA filings are updated from the SEC’s EDGAR system and can be paired with AI-generated summaries that explain the purpose and key points of each document in plain language. Users can quickly understand what a particular 8-K, Form 25 or future Form 15 means for Verona Pharma’s historical shareholders, how the cash consideration per share and per ADS was structured, and how the delisting and deregistration process unfolded. This makes it easier to interpret Verona Pharma’s regulatory history and the implications of its transition off the public markets.
Verona Pharma plc director Martin Edwards reported multiple transactions tied to the sale of the company under a scheme of arrangement with Merck/Vol Holdings. At the effective time each American Depositary Share (ADS) — representing eight ordinary shares — was paid
Verona Pharma plc (VRNA) reported insider changes tied to a takeover transaction effective
Kenneth Cunningham, a director of Verona Pharma plc (VRNA), reported multiple transactions tied to the company's scheme of arrangement with Merck/Parent on
Verona Pharma plc (VRNA) director Christina Ackermann reported several transactions tied to the completion of a scheme of arrangement under a transaction agreement with Merck/Parent and Bidco. At the effective time, each ADS (representing eight Ordinary Shares) entitled holders to
Verona Pharma plc filed an S-8 post-effective amendment that references previously filed registration statements covering Ordinary Shares issuable under its employee share plans. The filing lists multiple prior registrations and the number of Ordinary Shares added under each plan, including filings registering 214,000, 2,590,000, 14,333,000, 11,998,660, 65,102,504, 17,132,312, 24,000,000, 34,745,648 and 28,127,576 Ordinary Shares under various versions of the 2017 Incentive Award Plan and option schemes. The document is signed by Benjamin Lucas as Principal Executive Officer and Director and includes a second signature line for Ebru Can Temucin dated October 7, 2025.
Verona Pharma plc filed a post-effective amendment to register employee equity under multiple past S-8 registrations. The document lists several registration numbers that together add specific blocks of Ordinary Shares to existing share‑award plans, including recent additions of
Verona Pharma plc filed an S-8 post-effective amendment registering additional ordinary shares for employee equity plans. The filing lists earlier registration statements and shows successive increases to the pool of shares available under the Verona Pharma plc 2017 Incentive Award Plan and its Second Amended and Restated 2017 Incentive Award Plan, including registrations of 214,000, 2,590,000, 14,333,000, 11,998,660, 65,102,504, 17,132,312, 24,000,000, 34,745,648, and 28,127,576 Ordinary Shares across multiple prior filings. The document is signed by Benjamin Lucas as Principal Executive Officer and Director and by Ebru Can Temucin.